Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
ACAD - ACADIA Pharmaceuticals Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$33.83
DETAILS
HIGH:
$49.00
LOW:
$14.50
MEDIAN:
$36.00
CONSENSUS:
$33.83
UPSIDE:
22.22%
Stock News
Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD
Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the
BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD
BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,515,173 shares of the biopharmaceutical company's stock, valued at approximately $569,634,000. BlackRock Inc. owned 13.15% of ACADIA Pharmaceuticals
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad.
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?
Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations
As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales
Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago.
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson's disease psychosis treatment NUPLAZID increased.
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.
Avidity Partners Management LP Sells 93,933 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Avidity Partners Management LP cut its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 87.9% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,967 shares of the biopharmaceutical company's stock after selling 93,933 shares during the period. Avidity Partners Management LP's
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 1:30 p.m. Eastern Time. Live webcasts will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceuticals Acadia is commit.
HRMY or ACAD: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of these two stocks presents investors with the better value opportunity right now?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Price Targets
Acadia Pharmaceuticals price target raised to $38 from $37 at Deutsche Bank
$38.00
(was $30.31)
Deutsche Bank
Acadia Pharmaceuticals price target raised to $28 from $27 at Morgan Stanley
$28.00
(was $29.65)
Morgan Stanley
Acadia Pharmaceuticals price target raised to $49 from $45 at UBS
$49.00
(was $28.24)
UBS
Acadia Pharmaceuticals price target raised to $41 from $38 at Needham
$41.00
(was $29.41)
Ami Fadia
·
Needham
Acadia Pharmaceuticals price target raised to $27 from $26 at Morgan Stanley
$27.00
(was $29.11)
Morgan Stanley
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at RBC Capital on 'Strong Sales'
$37.00
(was $28.66)
Brian Abrahams
·
RBC Capital
Acadia Pharmaceuticals (ACAD) PT Raised to $25 at Oppenheimer
$25.00
(was $27.15)
Matthew Hershenhorn
·
Oppenheimer
Acadia Pharmaceuticals (ACAD) PT Raised to $14.50 at BofA Securities
$14.50
(was $26.01)
Raymond James
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital
$36.00
(was $25.27)
BMO Capital
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital
$36.00
(was $25.77)
Brian Abrahams
·
RBC Capital
Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank
$37.00
(was $25.06)
David Hoang
·
Deutsche Bank
Acadia Pharmaceuticals price target raised to $36 from $32 at Canaccord
$36.00
(was $25.32)
Sumant Kulkarni
·
Canaccord Genuity
Acadia Pharmaceuticals (ACAD) PT Lowered to $29 at BofA Securities
$29.00
(was $22.81)
William Blair
Acadia Pharmaceuticals initiated with an Outperform at Wolfe Research
$33.00
(was $24.73)
Rudy Li
·
Wolfe Research
Acadia Pharmaceuticals upgraded to Outperform from Neutral at Mizuho
$35.00
(was $23.99)
Mizuho Securities
Acadia Pharmaceuticals price target lowered to $31 from $35 at RBC Capital
$31.00
(was $26.13)
RBC Capital
Acadia Pharmaceuticals price target raised to $40 from $35 at UBS
$40.00
(was $26.66)
Ashwani Verma
·
UBS
Acadia Pharmaceuticals price target raised to $34 from $29 at Needham
$34.00
(was $26.29)
Needham
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at H.C. Wainwright
$37.00
(was $27.27)
Piper Sandler
Acadia Pharmaceuticals (ACAD) PT Raised to $37 at H.C. Wainwright
$37.00
(was $27.27)
Stifel Nicolaus